Medical Oncology 🏥 Hospital General Universitario Gregorio Marañón ⎪@myESMO Faculty 🫁 ⎪#endlungcancer #lcsm
Madrid, Spain
- Tweets 24,752
- Following 4,397
- Followers 12,194
- Likes 25,840
Pinned Tweet
🎉 Online first: After positive press release of IMforte trial, our timely published review of the MoA of #lurbinectedin and its implications for combinational therapies in #SCLC, including immunotherapy. #LCSM 🫁
Check it out here 👉aacrjournals.org/mct/article…
8
20
64
11,212
Thanks to all that joined us for a wonderful #ESMO26 lunch symposium on EGFR mutant NSCLC with Drs. @APassaroMD @HendriksLizza @Tony_Calles - an important opportunity to provide global perspectives on the evolving state of care.
3
13
1,105
Por tanto, la pauta de dosis en intervalos extendidos es potencialmente inferior a la administración convencional. Es decir, no se puede confirmar la hipótesis inicial y los pacientes tienen el riesgo de progresar antes y fallecen más rápido cuando no reciben la inmunoterapia en la posología establecida. Menos tóxico, menos eficaz. Red flag 🚩
🔬 #ESMO26 | MOIO (LBA10): administrar inmunoterapia cada 12 semanas no demostró ser no inferior a la pauta estándar.
🗣️ La Dra. Aitana Calvo, portavoz de @_SEOM y oncóloga médico del @HGregorioM explica los resultados de este estudio presentado en Sesión Presidencial del Congreso @myESMO.
🎬 ¡Con este vídeo cerramos nuestros 12 análisis de las Sesiones Presidenciales!
3
8
1,996
‼️ While understanding of PK/PD for immune-checkpoint is not fully explained, and personalization in an individualized basis can be justified, reduced frequency administration of ICI may led to worse clinical outcomes.
⚠️ Prospective MOIO non-inferiority trial suggests and stopped earlier due to futility, potential harm ❌
🫥 When data does not meet wishes. #ESMO26 #LCSM
1
3
8
625
Dr. Antonio Calles 🫁🚭 retweeted
Proud participation of our hospital 🏥 in the MDT-BRIDGE leading by @rosaalvarezal with a terrific publication. Congrats!!!! #ESMO26 #LCSM
🔥 Outstanding piece of work published today in Nature Medicine!
Huge congratulations to @MartinReck2 ,@NadalErnest , @DoctorJSpicer and @AndrearicFili , and the entire MDT-BRIDGE team on this important publication! 👏👏
The phase II MDT-BRIDGE trial, investigating neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable NSCLC, tackles a clinically relevant question: how can we push the boundaries of multidisciplinary treatment and offer more patients a chance of curative-intent therapy?
This is exactly the kind of collaborative clinical research we need: challenging established boundaries, asking meaningful questions, and ultimately striving to improve outcomes for our patients.
Congratulations to everyone involved! 👏
🔗 nature.com/articles/s41591-0…
Happy to continue sharing exciting advances in lung cancer research as an #ESMOAmbassadors
#ESMO26 #NatureMedicine #LungCancer #NSCLC #ThoracicOncology #Immunotherapy #ClinicalResearch #MultidisciplinaryCare #CancerResearch
3
8
547
Iza-Bren seems to provide efficacy in pretreated EGFR-mutated NSCLC compared to pt-based chemotherapy.
Better ORR and PFS, OS still immature, safety profile not such favorable compared to chemotherapy. Interesting to see global data, optimized AEs management. Good to have more potential options available. #ESMO26 #LCSM
5
8
444
Savo + Osi >>> Osi
In 1L stage IV, EGFRmut: Better PFS and remarkable 44.5 OS for a poor prognosis population, with the cost of more MET-related side effects.
High attrition to find MET-IHC3+. Wondering how this data compares to this subset of patients in the MARIPOSA trial. #ESMO26 #LCSM
1
4
14
661
#ESMO26 Day 4
After last night game, the last minutes of tonight’s full moon.
Ready to keep the pace! 💪
1
2
20
978
💥 Ivonescimab, bi-specific PD-1/VEGF, hits a 4th positive Phase III randomized clinical trial, first outside lung cancer indications already approved in China.
✅ 1 L Biliary-tract carcinoma: Ivo + chemo >> Durva + chemo, better ORR, PFS, and OS
#ESMO26
4
15
1,028
Dr. Antonio Calles 🫁🚭 retweeted
🎯 Join us this today at @DaiichiSankyo Satellite Symposium #ESMO26 and challenge your knowledge in biomarkers for ADCs in NSCLC #LCSM
3
6
431
Dr. Antonio Calles 🫁🚭 retweeted
Excellent discussion from Natasha Leighl contextualising Saffron study. MET amplification defined by previous Savannah study. Is IHC enough - yes!Control arm performs as expected, but note that MET is a poor prognostic marker
But less than a third have MET 3+.
#ESMO26 #LCSM
1
7
19
995
Presented at #ESMO26:
In patients with previously treated advanced non–small-cell lung cancer with a 𝘒𝘙𝘈𝘚 G12C mutation, median progression-free survival was 9.8 months with the KRAS G12C inhibitor divarasib and 5.7 months with sotorasib or adagrasib. Full phase 3 Krascendo 1 trial results: nej.md/4BiCvbk
@myESMO
ALT A graph from the Original Article "Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC.” The trial name, Krascendo 1, is in parentheses after the title. The graph shows progression-free survival in the full analysis population. The trial results are being presented at the European Society for Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.
1
2
18
1,402